FDA Puts Clinical Hold On Gilead's Magrolimab/Azacitidine Combo Trials In Blood Cancer SettingsBenzinga • 01/26/22
Vizient Pharmacy Market Outlook: Increased Use of Remdesivir for COVID Pushes it to Top Spot in Total Vizient Member SpendBusiness Wire • 01/26/22
Gilead Announces Partial Clinical Hold for Studies Evaluating Magrolimab in Combination With AzacitidineBusiness Wire • 01/25/22
Gilead Sciences (GILD) Gains But Lags Market: What You Should KnowZacks Investment Research • 01/25/22
Gilead (GILD) Drug Gets FDA Nod for Non-Hospitalized COVID PatientsZacks Investment Research • 01/24/22
FDA Approves Gilead's Remdesivir For Non-Hospitalized COVID-19 Patients At High Risk For Disease ProgressionBenzinga • 01/24/22
FDA Approves Veklury® (Remdesivir) for the Treatment of Non-Hospitalized Patients at High Risk for COVID-19 Disease ProgressionBusiness Wire • 01/21/22
Gilead Sciences to Release Fourth Quarter & Full Year 2021 Financial Results on Tuesday, February 1, 2022Business Wire • 01/18/22
Gilead Sciences, Inc.'s (GILD) CEO Daniel O'Day on JPMorgan 40th Annual Healthcare Conference (Transcript)Seeking Alpha • 01/10/22
Gilead Announces Clinical Trial Collaborations With Merck to Evaluate Trodelvy® in Combination With KEYTRUDA® in First-Line Metastatic Non-Small Cell Lung CancerBusiness Wire • 01/10/22